TRAP-1, the mitochondrial Hsp90

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 3, 2012, Pages 767-773

  Altieri, Dario C ^a,b   Stein, Gary S ^a,c   Lian, Jane B ^a,c   Languino, Lucia R ^a,d  

^a Prostate Cancer Discovery and Development Program   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Apoptosis; Chaperone; Mitochondria; Permeability transition pore; Tumor growth

Indexed keywords

CELL PROTEIN; HEAT SHOCK PROTEIN 90; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PROTEIN 1; UNCLASSIFIED DRUG;

CELL COMPARTMENTALIZATION; CELL ORGANELLE; DEGENERATIVE DISEASE; HOMEOSTASIS; HUMAN; INTERVENTION STUDY; MITOCHONDRION; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SIGNAL TRANSDUCTION;

EID: 84857059172     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.08.007     Document Type: Review

References (68)

1. Taipale M., Jarosz D.F., Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 2010, 11:515-528.
2. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
3. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10:537-549.
4. Young J.C., Barral J.M., Ulrich Hartl F. More than folding: localized functions of cytosolic chaperones. Trends Biochem. Sci. 2003, 28:541-547.
5. Eletto D., Dersh D., Argon Y. GRP94 in ER quality control and stress responses. Semin. Cell Dev. Biol. 2010, 21:479-485.
6. Felts S.J., Owen B.A., Nguyen P., Trepel J., Donner D.B., Toft D.O. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J. Biol. Chem. 2000, 275:3305-3312.
7. Wanderling S., Simen B.B., Ostrovsky O., Ahmed N.T., Vogen S.M., Gidalevitz T., Argon Y. GRP94 is essential for mesoderm induction and muscle development because it regulates insulin-like growth factor secretion. Mol. Biol. Cell 2007, 18:3764-3775.
8. Randow F., Seed B. Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat. Cell Biol. 2001, 3:891-896.
9. Baker-LePain J.C., Reed R.C., Nicchitta C.V. ISO: a critical evaluation of the role of peptides in heat shock/chaperone protein-mediated tumor rejection. Curr. Opin. Immunol. 2003, 15:89-94.
10. Luo B., Lam B.S., Lee S.H., Wey S., Zhou H., Wang M., Chen S.-Y., Adams G.B., Lee A.S. The endoplasmic reticulum chaperone protein GRP94 is required for maintaining hematopoietic stem cell interactions with the adult bone marrow niche. PLoS One 2011, 6:e20364.
11. McLaughlin M., Vandenbroeck K. The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?. Br. J. Pharmacol. 2010, 162:328-345.
12. Haynes C.M., Ron D. The mitochondrial UPR - protecting organelle protein homeostasis. J. Cell Sci. 2010, 123:3849-3855.
13. Song H.Y., Dunbar J.D., Zhang Y.X., Guo D., Donner D.B. Identification of a protein with homology to hsp90 that binds the type 1 tumor necrosis factor receptor. J. Biol. Chem. 1995, 270:3574-3581.
14. Chen C.F., Chen Y., Dai K., Chen P.L., Riley D.J., Lee W.H. A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock. Mol. Cell. Biol. 1996, 16:4691-4699.
15. Dutta R., Inouye M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 2000, 25:24-28.
16. Leskovar A., Wegele H., Werbeck N.D., Buchner J., Reinstein J. The ATPase cycle of the mitochondrial hsp90 analog Trap1. J. Biol. Chem. 2008, 283:11677-11688.
17. Chen B., Piel W.H., Gui L., Bruford E., Monteiro A. The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 2005, 86:627-637.
18. Cechetto J.D., Gupta R.S. Immunoelectron microscopy provides evidence that tumor necrosis factor receptor-associated protein 1 (TRAP-1) is a mitochondrial protein which also localizes at specific extramitochondrial sites. Exp. Cell Res. 2000, 260:30-39.
19. Pridgeon J.W., Olzmann J.A., Chin L.S., Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 2007, 5:e172.
20. Debatin K.M., Krammer P.H. Death receptors in chemotherapy and cancer. Oncogene 2004, 23:2950-2966.
21. Green D.R., Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004, 305:626-629.
22. Li J., Yuan J. Caspases in apoptosis and beyond. Oncogene 2008, 27:6194-6206.
23. 2-hydroxyisovalerylshikonin. J. Biol. Chem. 2004, 279:42503-42515.
24. Lu H., Hou Q., Zhao T., Zhang H., Zhang Q., Wu L., Fan Z. Granzyme M directly cleaves inhibitor of caspase-activated DNase (CAD) to unleash CAD leading to DNA fragmentation. J. Immunol. 2006, 177:1171-1178.
25. Hua G., Zhang Q., Fan Z. Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J. Biol. Chem. 2007, 282:20553-20560.
26. Im C.-N., Lee J.-S., Zheng Y., Seo J.-S. Iron chelation study in a normal human hepatocyte cell line suggests that tumor necrosis factor receptor-associated protein 1 (TRAP1) regulates production of reactive oxygen species. J. Cell. Biochem. 2007, 100:474-486.
27. Coller H.A., Grandori C., Tamayo P., Colbert T., Lander E.S., Eisenman R.N., Golub T.R. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. 2000, 97:3260-3265.
28. Costantino E., Maddalena F., Calise S., Piscazzi A., Tirino V., Fersini A., Ambrosi A., Neri V., Esposito F., Landriscina M. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Lett. 2009, 279:39-46.
29. Montesano Gesualdi N., Chirico G., Pirozzi G., Costantino E., Landriscina M., Esposito F. Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress 2007, 10:342-350.
30. Lang A.E., Lozano A.M. Parkinson's disease. N. Engl. J. Med. 1998, 339:1044-1053.
31. Schapira A.H.V., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 333:1269-1269.
32. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M.K., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., González-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
33. Petit A., Kawarai T., Paitel E., Sanjo N., Maj M., Scheid M., Chen F., Gu Y., Hasegawa H., Salehi-Rad S., Wang L., Rogaeva E., Fraser P., Robinson B., St George-Hyslop P., Tandon A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson's disease-related mutations. J. Biol. Chem. 2005, 280:34025-34032.
34. Kang B.H., Plescia J., Dohi T., Rosa J., Doxsey S.J., Altieri D.C. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007, 131:257-270.
35. Leav I., Plescia J., Goel H.L., Li J., Jiang Z., Cohen R.J., Languino L.R., Altieri D.C. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am. J. Pathol. 2010, 176:393-401.
36. Halestrap A.P. What is the mitochondrial permeability transition pore?. J. Mol. Cell. Cardiol. 2009, 46:821-831.
37. Baines C.P., Kaiser R.A., Sheiko T., Craigen W.J., Molkentin J.D. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat. Cell Biol. 2007, 9:550-555.
38. Kokoszka J.E., Waymire K.G., Levy S.E., Sligh J.E., Cai J., Jones D.P., MacGregor G.R., Wallace D.C. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004, 427:461-465.
39. He L., Lemasters J.J. Regulated and unregulated mitochondrial permeability transition pores: a new paradigm of pore structure and function?. FEBS Lett. 2002, 512:1-7.
40. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., Brunskill E.W., Sayen M.R., Gottlieb R.A., Dorn G.W., Robbins J., Molkentin J.D. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005, 434:658-662.
41. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005, 434:652-658.
42. Forte M., Gold B.G., Marracci G., Chaudhary P., Basso E., Johnsen D., Yu X., Fowlkes J., Bernardi P., Bourdette D. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc. Natl. Acad. Sci. 2007, 104:7558-7563.
43. Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., Yan Y., Wang C., Zhang H., Molkentin J.D., Gunn-Moore F.J., Vonsattel J.P., Arancio O., Chen J.X., Yan S.D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 2008, 14:1097-1105.
44. Kang B.H., Plescia J., Song H.Y., Meli M., Colombo G., Beebe K., Scroggins B., Neckers L., Altieri D.C. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 2009, 119:454-464.
45. Plescia J., Salz W., Xia F., Pennati M., Zaffaroni N., Daidone M.G., Meli M., Dohi T., Fortugno P., Nefedova Y., Gabrilovich D.I., Colombo G., Altieri D.C. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7:457-468.
46. Fortugno P., Beltrami E., Plescia J., Fontana J., Pradhan D., Marchisio P.C., Sessa W.C., Altieri D.C. Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:13791-13796.
47. Kim H.K., Choi I.J., Kim C.G., Kim H.S., Oshima A., Michalowski A., Green J.E. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One 2011, 6:e16694.
48. Ruiz-Romero C., Calamia V., Rocha B., Mateos J., Fernandez-Puente P., Blanco F.J. Hypoxia conditions differentially modulate human normal and osteoarthritic chondrocyte proteomes. J. Proteome Res. 2010, 9:3035-3045.
49. Landriscina M., Laudiero G., Maddalena F., Amoroso M.R., Piscazzi A., Cozzolino F., Monti M., Garbi C., Fersini A., Pucci P., Esposito F. Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents. Cancer Res. 2010, 70:6577-6586.
50. Ghosh J.C., Siegelin M.D., Dohi T., Altieri D.C. Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Res. 2010, 70:8988-8993.
51. Kang B.H., Siegelin M.D., Plescia J., Raskett C.M., Garlick D.S., Dohi T., Lian J.B., Stein G.S., Languino L.R., Altieri D.C. Preclinical characterization of mitochondria-directed, small molecule Hsp90 inhibitors, Gamitrinibs, in advanced prostate cancer. Clin. Can. Res. 2010, 16:4779-4788.
52. Kang B.H., Tavecchio M., Goel H.L., Hsieh C.C., Garlick D.S., Raskett C.M., Lian J.B., Stein G.S., Languino L.R., Altieri D.C. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. Br. J. Cancer 2011, 104:629-634.
53. Siegelin M.D., Dohi T., Raskett C.M., Orlowski G.M., Powers C.M., Gilbert C.A., Ross A.H., Plescia J., Altieri D.C. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J. Clin. Invest. 2011, 121:1349-1360.
54. Hetz C., Glimcher L.H. Fine-tuning of the unfolded protein response: assembling the IRE1alpha interactome. Mol. Cell 2009, 35:551-561.
55. Ron D., Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 2007, 8:519-529.
56. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
57. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nat. Rev. Cancer 2007, 7:961-967.
58. Baud V., Karin M. Is NF-[kappa]B a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8:33-40.
59. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 2008, 7:1001-1012.
60. Liu D., Hu J., Agorreta J., Cesario A., Zhang Y., Harris A.L., Gatter K., Pezzella F. Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Lett. 2010, 296:194-205.
61. Hayashi T., Su T.-P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007, 131:596-610.
62. Haynes C.M., Yang Y., Blais S.P., Neubert T.A., Ron D. The matrix peptide exporter HAF-1 signals a mitochondrial UPR by activating the transcription factor ZC376.7 in C. elegans. Mol. Cell 2010, 37:529-540.
63. Amuthan G., Biswas G., Zhang S.Y., Klein-Szanto A., Vijayasarathy C., Avadhani N.G. Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J. 2001, 20:1910-1920.
64. Giorgi C., De Stefani D., Bononi A., Rizzuto R., Pinton P. Structural and functional link between the mitochondrial network and the endoplasmic reticulum. Int. J. Biochem. Cell Biol. 2009, 41:1817-1827.
65. Chu C.T. A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease. Hum. Mol. Genet. 2010, 19:R28-37.
66. Ogata M., Hino S., Saito A., Morikawa K., Kondo S., Kanemoto S., Murakami T., Taniguchi M., Tanii I., Yoshinaga K., Shiosaka S., Hammarback J.A., Urano F., Imaizumi K. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol. Cell. Biol. 2006, 26:9220-9231.
67. Kang B.H., Altieri D.C. Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene 2009, 28:3681-3688.
68. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.